Search results
Results from the WOW.Com Content Network
After chemotherapy, Edmonds received the stem cell transplant — a high-risk procedure that has the potential to weaken the immune system — at City of Hope on Feb. 6, 2019.
Edmonds, the oldest potential cure case at 63 when he received a stem-cell transplant for AML in 2019, received reduced-intensity chemotherapy because of his age. Off antiretrovirals since March ...
Donor lymphocyte infusion is the infusion in which lymphocytes from the original stem cell donor are infused, after the transplant, to augment an anti-tumor immune response or ensure that the donor stem cells remain engrafted. [1] [2] These donated white blood cells contain cells of the immune system that can recognize and destroy cancer cells.
Stem-cell therapy uses stem cells to treat or prevent a disease or condition. [1] As of 2024, the only FDA-approved therapy using stem cells is hematopoietic stem cell transplantation. [2] [3] This usually takes the form of a bone marrow or peripheral blood stem cell transplantation, but the cells can also be derived from umbilical cord blood.
Stem-cell transplantation was pioneered using bone marrow-derived stem cells by a team at the Fred Hutchinson Cancer Research Center from the 1950s through the 1970s led by E. Donnall Thomas, whose work was later recognized with a Nobel Prize in Physiology or Medicine. Thomas' work showed that bone-marrow cells infused intravenously could ...
Stem cell donations save lives—and they are often a selfless act to help a stranger. But one case involving a Chicago man with leukemia shows it can help the donor too—in profound ways.
Peripheral blood stem cell transplantation (PBSCT), also called "Peripheral stem cell support", [1] is a method of replacing blood-forming stem cells.Stem cells can be destroyed through cancer treatments such as chemotherapy or radiation, as well as any blood-related diseases, such as leukemia, lymphoma, neuroblastoma and multiple myeloma. [2]
A novel approach to organ transplantation allowed patients to wean off anti-rejection drugs after two years, according to the results of a phase 3 clinical trial presented Monday.